chrM-3260-A-G
Variant summary
Our verdict is Likely pathogenic. The variant received 7 ACMG points: 7P and 0B. PS4_ModeratePS3_SupportingPP1_ModeratePP3PM2_Supporting
This summary comes from the ClinGen Evidence Repository: The m.3260A>G variant in MT-TL1 has been reported in five unrelated individuals with primary mitochondrial disease (PS4_moderate; PMIDs: 1677065, 8210299, 8941275, 20965148, 24656211). Three individuals had features variably consistent with MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; PMIDs: 8941275, 20965148, 24656211) and two individuals had cardiomyopathy and skeletal muscle myopathy (PMIDs: 1677065, 8210299). There are no reported de novo occurrences to our knowledge. This variant segregated with disease in one of the reported families, as five affected family members had heteroplasmy levels ranging from 86% - 90% whereas unaffected family members had heteroplasmy levels ranging from 20% - 78% (PP1_moderate; PMID:1677065). This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting). The computational predictor MitoTIP suggests this variant is pathogenic (81st percentile) and HmtVAR predicts it to be pathogenic score of 0.7 (PP3). Studies in cybrids and yeast support the functional impact of this variant (PS3_supporting; PMIDs: 8132749, 19631764). In summary, this variant meets criteria to be classified as likely pathogenic for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on May 22, 2023. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID:32906214): PS4_moderate, PP1_moderate, PM2_supporting, PP3, PS3_supporting. LINK:https://erepo.genome.network/evrepo/ui/classification/CA120566/MONDO:0044970/014
Frequency
Consequence
unassigned_transcript_4788 missense
Scores
Clinical Significance
Conservation
Publications
- mitochondrial diseaseInheritance: Mitochondrial Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 7 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| TRNL1 | unassigned_transcript_4788 | c.31A>G | p.Lys11Glu | missense_variant | Exon 1 of 1 | |||
| ND1 | unassigned_transcript_4789 | c.-47A>G | upstream_gene_variant | |||||
| RNR2 | unassigned_transcript_4787 | n.*31A>G | downstream_gene_variant |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MT-TL1 | ENST00000386347.1 | n.31A>G | non_coding_transcript_exon_variant | Exon 1 of 1 | 6 | |||||
| MT-ND1 | ENST00000361390.2 | c.-47A>G | upstream_gene_variant | 6 | ENSP00000354687.2 | |||||
| MT-RNR2 | ENST00000387347.2 | n.*31A>G | downstream_gene_variant | 6 |
Frequencies
Mitomap
ClinVar
Submissions by phenotype
MELAS syndrome Pathogenic:1Other:1
- -
The NC_012920.1:m.3260A>G variant in MT-TL1 gene is interpreted to be a Pathogenic variant based on the modified ACMG guidelines (unpublished). This variant meets the following evidence codes reported in the guidelines: PS3, PS5, PM7 -
Mitochondrial disease Pathogenic:1
The m.3260A>G variant in MT-TL1 has been reported in five unrelated individuals with primary mitochondrial disease (PS4_moderate; PMIDs: 1677065, 8210299, 8941275, 20965148, 24656211). Three individuals had features variably consistent with MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; PMIDs: 8941275, 20965148, 24656211) and two individuals had cardiomyopathy and skeletal muscle myopathy (PMIDs: 1677065, 8210299). There are no reported de novo occurrences to our knowledge. This variant segregated with disease in one of the reported families, as five affected family members had heteroplasmy levels ranging from 86% - 90% whereas unaffected family members had heteroplasmy levels ranging from 20% - 78% (PP1_moderate; PMID: 1677065). This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting). The computational predictor MitoTIP suggests this variant is pathogenic (81st percentile) and HmtVAR predicts it to be pathogenic score of 0.7 (PP3). Studies in cybrids and yeast support the functional impact of this variant (PS3_supporting; PMIDs: 8132749, 19631764). In summary, this variant meets criteria to be classified as likely pathogenic for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on May 22, 2023. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PS4_moderate, PP1_moderate, PM2_supporting, PP3, PS3_supporting. -
MITOCHONDRIAL CARDIOMYOPATHY WITH OR WITHOUT SKELETAL MYOPATHY Pathogenic:1
- -
Computational scores
Source: